SCHEMBL11949060

SCHEMBL11949060

CCN(CC)c1cc2[nH]c(-c3ccccc3OC)nc2cc1NC(=O)C1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ KMT2A Q03164 4/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HTT P42858 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ FOXO1 Q12778 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ TP53 P04637 1/20 0.43
▸ S1PR1 P21453 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11948986 0.99 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AKDM4EALDH1A1RAB9A
SCHEMBL15275517 0.97 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AKDM4EALDH1A1RAB9A
SCHEMBL11949067 0.95 KMT2A (0.47) SMN1; SMN2KMT2AHTTNPSR1ABL1
SCHEMBL14046891 0.88 RAB9A (0.48) SMN1; SMN2KMT2AKDM4EALDH1A1RAB9A
SCHEMBL11948989 0.85 ABL1 (0.47) ABL1HSD17B10HDAC6
SCHEMBL11949046 0.85 ALOX15 (0.48) MAPTABL1HSD17B10HDAC6
SCHEMBL3092628 0.84 KDM4E (0.52) SMN1; SMN2KMT2AKDM4EALDH1A1RAB9A
SCHEMBL11949040 0.84 ADORA3 (0.49) KDM4EHTTNPSR1TP53S1PR1
SCHEMBL14046899 0.83 KMT2A (0.51) SMN1; SMN2KMT2AKDM4EALDH1A1RAB9A
SCHEMBL11949030 0.83 ADORA3 (0.48) KDM4EHTTNPSR1TP53NR2E3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232410-B2 Benzimidazoles and pharmaceutical compositions thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2012-07-31 — — US disclosed
US-8232410-B2 Benzimidazoles and pharmaceutical compositions thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2012-07-31 — — US disclosed
US-20100256203-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2010-10-07 — — US disclosed
US-20100256203-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256203-A1 BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF TBCD, TBC1D5, CFTR SMN1; SMN2 2448/4885KMT2A 3023/4885KDM4E 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback